Lanreotide; 108736-35-2; factory supply peptide 98% white to off-white powder
108736-35-2
98%
1g,10g,20g
2023-07-30
Thymalfasin,Terlipressin,Carbetocin,Custom peptide,Semaglutide,Desmorpressin
-
Product Details
-
Seller Information
-
DescriptionECHEMI Editorial ReferenceWhite to off-white lyophilised powder
Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, Ipsen Pharmaceuticals as lanreotide acetate, and marketed as Somatuline. It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.|Lanreotide is a synthetic polypeptide analogue of somatostatin that resembles the native hormone in its ability to suppress levels and activity of growth hormone, insulin, glucagon and many other gastrointestinal peptides. Because its half-life is longer than somatostatin, lanreotide can be used clinically to treat neuroendocrine tumors that secrete excessive amounts of growth hormone (acromegaly) or other active hormones or neuropeptides. Lanreotide has many side effects including suppression of gall bladder contractility and bile production, and maintenance therapy may cause cholelithiasis and pancreatitis as well accompanying liver injury.|Octreotide is a synthetic somatostatin analogue that resembles the native polypeptide in its activity in suppressing levels and activity of growth hormone, insulin, glucagon and many other gastrointestinal peptides. Because its half-life is longer than somatostatin, octreotide can be used clinically to treat neuroendocrine tumors that secrete excessive amounts of growth hormone (acromegaly) or other active hormones or neuropeptides. Octreotide has many side effects including suppression of gall bladder contractility and bile production, and maintenance therapy can cause cholelithiasis, pancreatitis as well as clinically apparent liver injury.|Pasireotide is a synthetic polypeptide analogue of somatostatin that resembles the native hormone in its ability to suppress levels and activity of growth hormone, insulin, glucagon and many other gastrointestinal peptides. Because its half-life is longer than somatostatin, pasireotide can be used clinically to treat neuroendocrine pituitary tumors that secrete excessive amounts of growth hormone causing acromegaly, or adrenocorticotropic hormone (ACTH) causing Cushing disease. Pasireotide has many side effects including suppression of gall bladder contractility and bile production, and maintenance therapy can cause cholelithiasis and accompanying elevations in serum enzymes and bilirubin.Research & Reference NoteLanreotide; 108736-35-2; factory supply peptide 98% white to off-white powder is listed on ECHEMI for industrial / laboratory sourcing. This listing is for industrial and laboratory research use. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Authoritative sourcesDisclaimer: This listing is for industrial and laboratory research use. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Reviewed by ECHEMI Scientific Review - Platform editorial review for research chemicals
Basic Info-
Product Name:
Lanreotide
Other Name:AUTOGEL;BETA-(2-NAPHTHYL)-D-ALA-CYS-TYR-D-TRP-LYS-VAL-CYS-THR AMIDE;BIM-23014;ANGIOPEPTIN;H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2;H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2, (DISULFIDE BOND);IPSTYL
CAS No.:108736-35-2
Molecular Formula:C54H69N11O10S2
InChIKeys:PUDHBTGHUJUUFI-UHFFFAOYSA-N
Molecular Weight:1096.32
Exact Mass:1095.467041
EC Number:1592732-453-0
ATC Code:H - Systemic hormonal preparations, excl. sex hormones and insulins
Categories:
Characteristics-
PSA:
405.68000
XLogP3:2.89
Density:1.40±0.1 g/cm3(Predicted)
Boiling Point:1508.2±65.0 °C(Predicted)
Flash Point:865.9±34.3 °C
Refractive Index:1.689
Storage Conditions:−20°C
Hazard IdentificationClassification of the substance or mixture
Reproductive toxicity, Category 2
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Warning
Hazard statement(s) H361 Suspected of damaging fertility or the unborn child
Precautionary statement(s) Prevention P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
Response P318 IF exposed or concerned, get medical advice.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Thymalfasin,Terlipressin,Carbetocin,Custom peptide,Semaglutide,Desmorpressin
-
Location:
No.199, East Huayuan Road, Mudu, Suzhou, China 215101
-
Payment Terms:
TT against copy of documents,L/C
-
Average lead Time:
20 days
-
Total Annual Revenue:
$25 million-$50 million
-
Total Employees:
301-500
-
Year of Establishment:
2000
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
